Analysts See $-0.58 EPS for Karyopharm Therapeutics Inc. (KPTI)

February 20, 2018 - By Nellie Frank

 Analysts See $ 0.58 EPS for Karyopharm Therapeutics Inc. (KPTI)
Investors sentiment increased to 2.5 in Q3 2017. Its up 0.94, from 1.56 in 2017Q2. It is positive, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported.
C Worldwide Group Incorporated Holdg A S holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 18,515 shares. Georgia-based Voya Mgmt Lc has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Deutsche Financial Bank Ag, Germany-based fund reported 162,265 shares. D E Shaw reported 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Goldman Sachs Group Inc Incorporated has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Natl Bank Of Mellon Corporation, New York-based fund reported 163,810 shares. State Of Wisconsin Inv Board owns 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 26,000 shares. Thomas J Herzfeld Advsrs has 0.02% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Iguana Healthcare Mngmt Ltd Limited Liability Company owns 400,000 shares or 2.45% of their US portfolio. Jacobs Levy Equity Management accumulated 24,600 shares. New York-based Opus Point Partners Limited Liability Company has invested 0.99% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Virtu Financial Limited Liability holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 18,293 shares. Moreover, Swiss Comml Bank has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 56,850 shares. Dimensional Fund Advisors L P holds 319,042 shares or 0% of its portfolio. Moreover, Fmr Limited Com has 0.01% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Since August 29, 2017, it had 0 insider buys, and 17 sales for $1.27 million activity. Another trade for 10,000 shares valued at $91,553 was sold by Shacham Sharon. Shares for $100,882 were sold by Kauffman Michael. Primiano Christopher Brett sold $277,872 worth of stock or 27,042 shares.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.58 EPS on March, 15.They anticipate $0.07 EPS change or 10.77 % from last quarter’s $-0.65 EPS. After having $-0.65 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -10.77 % EPS growth. The stock increased 1.42% or $0.21 during the last trading session, reaching $14.98. About 377,939 shares traded or 76.62% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 20, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. On Friday, May 27 the stock rating was initiated by Raymond James with “Outperform”. JP Morgan maintained it with “Overweight” rating and $19 target in Monday, March 14 report. The company was initiated on Tuesday, June 28 by Robert W. Baird. The firm earned “Hold” rating on Wednesday, January 6 by Jefferies. The company was maintained on Wednesday, August 12 by MLV. Jefferies maintained the shares of KPTI in report on Thursday, October 12 with “Buy” rating. H.C. Wainwright initiated it with “Buy” rating and $15 target in Thursday, August 18 report. The stock has “Buy” rating by Canaccord Genuity on Tuesday, August 8. H.C. Wainwright maintained the shares of KPTI in report on Thursday, September 8 with “Buy” rating. Jefferies maintained the shares of KPTI in report on Tuesday, March 15 with “Hold” rating.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $742.01 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

More important recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Globenewswire.com which released: “Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule …” on February 01, 2018, also Globenewswire.com published article titled: “Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment …”, Seekingalpha.com published: “Karyopharm Therapeutics: Buy, Sell, Or Hold?” on June 30, 2017. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was released by: Seekingalpha.com and their article: “What’s Next For Karyopharm Therapeutics?” with publication date: December 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: